Big Pharma Split Corp (PRM) Fair Value & Analysis
Financial Services · CA · Market cap C$17.8M
Fair value as of: Jun 26, 2026
From 13 valuation models · updated 3 days ago
Share price +3.3% over the past month.
Price vs Fair Value (12 months)
12‑month range C$9.44 – C$14.43 · fair‑value band C$14.71 – C$24.51 · the C$13.57 price screens below the C$19.61 fair value. As of Jun 26, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Big Pharma Split Corp (PRM) currently trades at C$13.57, while our model-based Fair Value estimate is C$19.61 — implying the stock looks roughly 44.5% undervalued today. We read business quality at 95/100 (high quality), in the Financial Services sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
Over the trailing twelve months, Big Pharma Split Corp generated revenue of C$5.1M at a net margin of 86.1%. It earns a return on equity of 27.6%. Net debt stands at C$11.8M. Fundamentals as of Jun 26, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
Big Pharma Split Corp is a closed ended equity mutual fund launched and managed by Harvest Portfolios Group Inc. It invests in the public equity markets across United States. The fund primarily invests in the Pharmaceutical sector. Big Pharma Split Corp was formed on September 15, 2017 and is domiciled in Canada.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Big Pharma Split Corp reported revenue of C$1.5M in FY2025 versus C$5.4M in FY2021, a compound −27.8%/yr. Reported net income was C$4.4M in FY2025, compounding −2.4%/yr from FY2021.
Open the full interactive analysis →
Similar stocks
6 more Asset Management stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Fondul Proprietatea SA FP | $4.20 | $6.41 | +53% |
| The Schiehallion Fund Limited MNTN | $2.27 | $4.54 | +100% |
| BlackRock, Inc BLK | 17,417 MXN | 10,294 MXN | -41% |
| BH Macro Limited BHMU | $0.0442 | $0.0900 | +104% |
| Blackstone Inc BX | $123.26 | $52.88 | -57% |
| Investor AB IVSBF | $39.99 | $79.98 | +100% |
Explore undervalued stocks
More undervalued Financial Services stocks →
Frequently asked questions
Is Big Pharma Split Corp (PRM) undervalued?
What is the fair value of PRM?
What is the quality score of PRM?
What is the revenue of Big Pharma Split Corp (PRM)?
What is the net profit margin of PRM?
Does Big Pharma Split Corp pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.